OTCMKTS:ENZN Enzon Pharmaceuticals (ENZN) Stock Price, News & Analysis $0.10 0.00 (-0.10%) As of 03/28/2025 02:43 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartFinancialsSEC FilingsShort InterestBuy This Stock About Enzon Pharmaceuticals Stock (OTCMKTS:ENZN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Enzon Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.10▼$0.1150-Day Range$0.09▼$0.1752-Week Range$0.06▼$0.24Volume21,000 shsAverage Volume82,695 shsMarket Capitalization$7.70 millionP/E Ratio10.39Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEnzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.Read More… Remove Ads Enzon Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks29th Percentile Overall ScoreENZN MarketRank™: Enzon Pharmaceuticals scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Enzon Pharmaceuticals. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Enzon Pharmaceuticals is 10.39, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 22.59.Price to Earnings Ratio vs. SectorThe P/E ratio of Enzon Pharmaceuticals is 10.39, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.62.Read more about Enzon Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.01% of the float of Enzon Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEnzon Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Enzon Pharmaceuticals has recently decreased by 12.33%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldEnzon Pharmaceuticals does not currently pay a dividend.Dividend GrowthEnzon Pharmaceuticals does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Enzon Pharmaceuticals is 1,201.20%. Payout ratios above 75% are not desirable because they may not be sustainable.Read more about Enzon Pharmaceuticals' dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.01% of the float of Enzon Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEnzon Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Enzon Pharmaceuticals has recently decreased by 12.33%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News SentimentN/A News SentimentEnzon Pharmaceuticals has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Enzon Pharmaceuticals this week, compared to 0 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Enzon Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.40% of the stock of Enzon Pharmaceuticals is held by insiders.Read more about Enzon Pharmaceuticals' insider trading history. Receive ENZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enzon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ENZN Stock News HeadlinesEnzon Pharmaceuticals Expands Board and Forms Strategic CommitteeJanuary 10, 2025 | tipranks.comUS Penny Stocks Spotlight: Enzon Pharmaceuticals And 2 More To ConsiderDecember 13, 2024 | finance.yahoo.comAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest economic transformation in American history. See, there's one particular part of Elon and Trump's plans that you need to pay special attention to right now.March 31, 2025 | Altimetry (Ad)Enzon Pharmaceuticals Inc ENZNNovember 8, 2023 | morningstar.comOKYO Pharma Limited (OK10.F)October 25, 2023 | finance.yahoo.comRegeneron Pharmaceuticals, Inc. Common Stock (REGN)July 30, 2023 | nasdaq.comEnzon Stock Hits New 52-Week Low (ENZN)March 26, 2023 | thestreet.comIbnsina Pharma Co (ISPH)March 20, 2023 | investing.comSee More Headlines ENZN Stock Analysis - Frequently Asked Questions How have ENZN shares performed this year? Enzon Pharmaceuticals' stock was trading at $0.1561 at the beginning of 2025. Since then, ENZN shares have decreased by 33.5% and is now trading at $0.1038. View the best growth stocks for 2025 here. How were Enzon Pharmaceuticals' earnings last quarter? Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) issued its quarterly earnings results on Thursday, April, 30th. The biotechnology company reported ($0.01) EPS for the quarter. How do I buy shares of Enzon Pharmaceuticals? Shares of ENZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Enzon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enzon Pharmaceuticals investors own include Biocept (BIOC), Aeterna Zentaris (AEZS), Energy Transfer (ET), DURECT (DRRX), Nymox Pharmaceutical (NYMX), OpGen (OPGN) and BioCryst Pharmaceuticals (BCRX). Company Calendar Last Earnings4/30/2020Today3/31/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolOTCMKTS:ENZN Previous SymbolNASDAQ:ENZN CIK727510 Webwww.enzon.com Phone(732) 980-4500Fax732-980-4585EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.01 Trailing P/E Ratio10.39 Forward P/E RatioN/A P/E GrowthN/ANet Income$1.37 million Net MarginsN/A Pretax Margin5,103.85% Return on Equity48.32% Return on Assets3.22% Debt Debt-to-Equity RatioN/A Current Ratio107.24 Quick Ratio107.24 Sales & Book Value Annual Sales$30,000.00 Price / Sales256.78 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares74,215,000Free Float73,918,000Market Cap$7.70 million OptionableNot Optionable Beta0.26 Social Links The 10 Best Stocks to Own: Spring 2025Discover the 10 best stocks to own in Spring 2025, carefully selected for their growth potential amid market volatility. This exclusive report highlights top companies poised to thrive in uncertain economic conditions—download now to gain an investing edge.Get This Free Report This page (OTCMKTS:ENZN) was last updated on 3/31/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enzon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enzon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.